argenx to Present Comprehensive Immunology Data at 2025 AANEM Annual Meeting and MGFA Scientific Session
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to improving the lives of people with severe autoimmune diseases, will present a wide range of clinical and real-world data for its lead therapy VYVGART® (IV: efgartigimod alfa-fcab; SC/Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) and its investigational candidate empasiprubart at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session. The meetings will be held in San Francisco from October 29 to November 1, 2025.
Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx, commented, “We’re proud to have a robust presence at this year’s AANEM and MGFA meetings, where we are presenting pivotal data and meaningful evidence across a broad spectrum of serious neuromuscular diseases, including myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and idiopathic inflammatory myopathy (IIM). The breadth of studies reflects the strength and momentum of our clinical programs, from expanding VYVGART into new patient populations to advancing empasiprubart. These presentations underscore our commitment to generating evidence that drives innovation and improves patient outcomes.”
VYVGART in Generalized Myasthenia Gravis (gMG)
argenx will present results from the Phase 3 ADAPT SERON study, which evaluated VYVGART for adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody-negative. The study demonstrated clinically meaningful improvements in disease activity across all subtypes, including triple negative, MuSK, and LRP4-Ab seropositive populations.
Interim data from the ADAPT Jr study will also be presented, providing insights on age-appropriate dosing, safety, and clinical effects of VYVGART in juvenile gMG patients.
CIDP Innovation with VYVGART Hytrulo and Empasiprubart
VYVGART Hytrulo data in CIDP will highlight functional improvements, long-term safety, and characteristics of real-world patients, emphasizing the importance of early treatment with effective, well-tolerated therapies.
argenx is advancing empasiprubart in CIDP through two Phase 3 studies – EMVIGORATE and EMNERGIZE – showcasing its commitment to developing innovative therapies that can improve outcomes for patients living with this debilitating condition.
Empasiprubart Development in MMN
Data from the Phase 2 ARDA study will present clinical efficacy and safety of empasiprubart in patients with multifocal motor neuropathy. The upcoming Phase 3 EMPASSION study will evaluate empasiprubart versus intravenous immunoglobulin (IVIg) in adults with MMN. Additionally, real-world data will highlight disease burden, management, and quality-of-life considerations, reinforcing the need for therapeutic approaches that reduce reliance on burdensome treatments while improving functional outcomes.
AANEM and MGFA Presentation Details
argenx will feature a comprehensive slate of oral and poster presentations across multiple neuromuscular disease areas. Key oral presentations at the MGFA session include:
- gMG: Phase 3 trial results in anti-AChR antibody-negative patients – Presenter: James F. Howard (October 29, 10:40 a.m. PT)
- Juvenile gMG: Interim ADAPT Jr study results – Presenter: Abigail N. Schwaede (October 29, 10:20 a.m. PT)
- Glucocorticoid Reduction: 18-month real-world claims data – Presenter: Neelam Goyal (October 29, 1:16 p.m. PT)
Poster presentations at both AANEM and MGFA cover a wide range of topics, including:
- Long-term efficacy and safety of intravenous and subcutaneous VYVGART in adult and juvenile gMG patients
- Real-world disease burden, management, and quality-of-life data for gMG, CIDP, and MMN
- Phase 3 designs for empasiprubart studies in CIDP and MMN
- Exploratory analyses of idiopathic inflammatory myopathy (IIM) outcomes
- FcRn blockade mechanisms, pharmacokinetics, and usability of subcutaneous VYVGART PH20
- COVID-19 vaccine responses among participants receiving intravenous and subcutaneous VYVGART
